Splash Beverage Group acquires exclusive worldwide license for CannEpil® epilepsy drug; issues $5.5M Series D preferred

SPLASH BEVERAGE GROUP, INC.

Exclusive worldwide rights to CannEpil® (CBD/THC) for drug-resistant epilepsy; Licensor gets 15% royalty on net revenue.
SBEV issues 5,500 shares of Series D Convertible Preferred (stated value $5.5M) to Licensor's noteholder as part of consideration.
C/M Capital commits to invest at least $1M in SBEV within 60 days; also $1M sales bonus upon $5M cumulative net revenue.
Development milestones: initiate Phase I trial within 24 months, Phase II within 48 months, file NDA after successful trials.
Licensor may terminate if SBEV fails to obtain US regulatory approval within 5 years; initial term 20 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.